ERBB2 and gastric cancer: SPOTLIGHT was a global phase three trial conducted across 215 sites to evaluate the efficacy of Zolbetuximab plus chemotherapy (mFOLFOX6) versus chemotherapy alone in patients with CLDN18.2-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced unresectable or metastatic GC/GEJ.